VALN · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $0.5B · 674 employees
197
SEC Filings
$5.38
Close 2026-06-18
674
Employees
Business Summary
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Its commercial products include IXIARO (Japanese encephalitis vaccine), DUKORAL (cholera/traveler's diarrhea vaccine), and IXCHIQ (chikungunya vaccine). Its lead pipeline candidate is VLA15, a Lyme disease vaccine developed in partnership with Pfizer, currently in Phase 3 clinical trials.
Look up VALN using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on VALN, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/VALN (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.